TY - JOUR
T1 - Individualized estimates of overdiagnosis in screen-detected prostate cancer
AU - Gulati, Roman
AU - Inoue, Lurdes Y.T.
AU - Gore, John L.
AU - Katcher, Jeffrey
AU - Etzioni, Ruth
PY - 2014/2
Y1 - 2014/2
N2 - Background: The chance that a prostate cancer detected by screening is overdiagnosed (ie, it would not have been detected in the absence of screening) can vary widely depending on the patient's age and tumor characteristics. The purpose of this study is to use age, Gleason score, and prostate-specific antigen (PSA) level to help inform patients with screen-detected prostate cancers about the chances their cancers were overdiagnosed. Methods: A computer microsimulation model of prostate cancer natural history was used to generate virtual life histories in the presence and absence of PSA screening, including an indicator of whether screen-detected cancers are overdiagnosed. A logistic regression model was fit to nonmetastatic patients diagnosed by screening with PSA less than 10 ng/mL, and a nomogram was created to predict the individualized risk of overdiagnosis given age, Gleason score, and PSA at diagnosis. Results: The calibrated microsimulation model closely reproduces observed incidence trends in the Surveillance, Epidemiology, and End Results registries by age, stage, and Gleason score. The fitted logistic regression predicts risks of overdiagnosis among PSA-detected patients with an area under the curve of 0.75. Chances of overdiagnosis range from 2.9% to 88.1%. Conclusions: The chances of overdiagnosis vary considerably by age, Gleason score, and PSA at diagnosis. The overdiagnosis nomogram presents tailored estimates of these risks based on patient and tumor information known at diagnosis and can be used to inform decisions about treating PSA-detected prostate cancers.
AB - Background: The chance that a prostate cancer detected by screening is overdiagnosed (ie, it would not have been detected in the absence of screening) can vary widely depending on the patient's age and tumor characteristics. The purpose of this study is to use age, Gleason score, and prostate-specific antigen (PSA) level to help inform patients with screen-detected prostate cancers about the chances their cancers were overdiagnosed. Methods: A computer microsimulation model of prostate cancer natural history was used to generate virtual life histories in the presence and absence of PSA screening, including an indicator of whether screen-detected cancers are overdiagnosed. A logistic regression model was fit to nonmetastatic patients diagnosed by screening with PSA less than 10 ng/mL, and a nomogram was created to predict the individualized risk of overdiagnosis given age, Gleason score, and PSA at diagnosis. Results: The calibrated microsimulation model closely reproduces observed incidence trends in the Surveillance, Epidemiology, and End Results registries by age, stage, and Gleason score. The fitted logistic regression predicts risks of overdiagnosis among PSA-detected patients with an area under the curve of 0.75. Chances of overdiagnosis range from 2.9% to 88.1%. Conclusions: The chances of overdiagnosis vary considerably by age, Gleason score, and PSA at diagnosis. The overdiagnosis nomogram presents tailored estimates of these risks based on patient and tumor information known at diagnosis and can be used to inform decisions about treating PSA-detected prostate cancers.
UR - http://www.scopus.com/inward/record.url?scp=84893845633&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893845633&partnerID=8YFLogxK
U2 - 10.1093/jnci/djt367
DO - 10.1093/jnci/djt367
M3 - Article
C2 - 24399850
AN - SCOPUS:84893845633
SN - 0027-8874
VL - 106
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 2
ER -